Duramorph Side Effects Center

Last updated on RxList: 10/14/2020
Duramorph Side Effects Center

What Is Duramorph?

Duramorph (morphine injection) is a narcotic pain reliever (opiate-type) used to treat severe pain. Duramorph is available in generic form.

What Are Side Effects of Duramorph?

Common side effects of Duramorph include:

  • nausea,
  • vomiting,
  • constipation,
  • lightheadedness,
  • dizziness,
  • drowsiness,
  • increased sweating,
  • urinary retention,
  • headache, or
  • dry mouth.

If Duramorph is injected, pain, redness, itching, or swelling at the injection site may occur. Tell your doctor if you have serious side effects of Duramorph including:

  • mental/mood changes (such as agitation, hallucinations, confusion),
  • difficulty urinating,
  • vision changes,
  • slow or fast heartbeat,
  • severe stomach or abdominal pain, or
  • changes in the amount of urine.

Dosage for Duramorph

The initial adult dose of Duramorph is 2 mg to 10 mg/70 kg of body weight.

What Drugs, Substances, or Supplements Interact with Duramorph?

Duramorph may interact with naltrexone, cimetidine, rifampin, certain medications for pain, alcohol, anti-seizure drugs, medicine for sleep or anxiety, muscle relaxants, other narcotic pain relievers, and psychiatric medicines. Check labels on all medicines (such as cough-and-cold products) because they may contain ingredients that cause drowsiness. Tell your doctor about all medications you are taking.

Duramorph During Pregnancy and Breastfeeding

During pregnancy, Duramorph should be used only when prescribed. Infants born to mothers who have used this medication may have withdrawal symptoms such as irritability, abnormal/persistent crying, vomiting, or diarrhea. Tell your doctor if you notice these symptoms in your newborn. This drug passes into breast milk and the effect on a nursing infant is not known. Consult your doctor before breastfeeding. Duramorph may cause withdrawal symptoms (such as restlessness, watery eyes, widened pupils, sweating, runny nose) if you suddenly stop using it.

Additional Information

Our Duramorph (morphine injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Medically speaking, the term "myalgia" refers to what type of pain? See Answer
Duramorph Professional Information


The most serious adverse experience encountered during administration of DURAMORPH (morphine injection) is respiratory depression and/or respiratory arrest. This depression and/or respiratory arrest may be severe and could require intervention. (See WARNINGS and OVERDOSAGE.) Because of delay in maximum CNS effect with intravenously administered drug (30 min), rapid administration may result in overdosing. Single-dose neuraxial administration may result in acute or delayed respiratory depression for periods at least as long as 24 hours.

Tolerance and Myoclonus

See WARNINGS for discussion of these and related hazards.

While low doses of intravenously administered morphine have little effect on cardiovascular stability, high doses are excitatory, resulting from sympathetic hyperactivity and increase in circulating catecholamines. Excitation of the central nervous system, resulting in convulsions, may accompany high doses of morphine given intravenously. Dysphoric reactions may occur after any size dose and toxic psychoses have been reported.


Single-dose epidural or intrathecal administration is accompanied by a high incidence of pruritus that is dose-related but not confined to the site of administration. Pruritus, following continuous infusion of epidural or intrathecal morphine, is occasionally reported in the literature; these reactions are poorly understood as to their cause.

Urinary Retention

Urinary retention, which may persist 10 to 20 hours following single epidural or intrathecal administration, is a frequent side effect and must be anticipated primarily in male patients, with a somewhat lower incidence in females. Also frequently reported in the literature is the occurrence of urinary retention during the first several days of hospitalization for the initiation of continuous intrathecal or epidural morphine therapy. Patients who develop urinary retention have responded to cholinomimetic treatment and/or judicious use of catheters (see PRECAUTIONS).


Constipation is frequently encountered during continuous infusion of morphine; this can usually be managed by conventional therapy.


Lumbar puncture-type headache is encountered in a significant minority of cases for several days following intrathecal catheter implantation; this, generally, responds to bed rest and/or other conventional therapy.


Other adverse experiences reported following morphine therapy include—Dizziness, euphoria, anxiety, hypotension, confusion, reduced male potency, decreased libido in men and women, and menstrual irregularities including amenorrhea, depression of cough reflex, interference with thermal regulation and oliguria. Evidence of histamine release such as urticaria, wheals and/or local tissue irritation may occur. Nausea and vomiting are frequently seen in patients following morphine administration.

Pruritus, nausea/vomiting and urinary retention, if associated with continuous infusion therapy, may respond to intravenous administration of a low dose of naloxone (0.2 mg). The risks of using narcotic antagonists in patients chronically receiving narcotic therapy should be considered.

In general, side effects are amenable to reversal by narcotic antagonists.


Drug Abuse And Dependence

Controlled Substance

Morphine sulfate is a Schedule II narcotic under the United States Controlled Substance Act (21 U.S.C. 801-886).

Morphine is the most commonly cited prototype for narcotic substances that possess an addiction-forming or addiction-sustaining liability. A patient may be at risk for developing a dependence to morphine if used improperly or for overly long periods of time. As with all potent opioids which are µ-agonists, tolerance as well as psychological and physical dependence to morphine may develop irrespective of the route of administration (intravenous, intramuscular, intrathecal, epidural or oral). Individuals with a prior history of opioid or other substance abuse or dependence, being more apt to respond to the euphorogenic and reinforcing properties of morphine, would be considered to be at greater risk.

Care must be taken to avert withdrawal in patients who have been maintained on parenteral/oral narcotics when epidural or intrathecal administration is considered. Withdrawal symptoms may occur when morphine is discontinued abruptly or upon administration of a narcotic antagonist.

Read the entire FDA prescribing information for Duramorph (Morphine Injection)


Back Pain: 16 Back Pain Truths and Myths See Slideshow

© Duramorph Patient Information is supplied by Cerner Multum, Inc. and Duramorph Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors